Kinnate Zeroes In On BRAF Subpopulation For Exarafenib Development Strategy
BeiGene And Partners Present RAF Dimer Inhibitor Data
Kinnate presented early monotherapy and combination data for its pan-RAF inhibitor at AACR, but its prioritization of BRAF Class II drew analyst concerns that its focus might be too narrow.
